The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1333-1340

  Mahmoudi, Mandana ^a   Sobieraj, Diana M ^b  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

cost effectiveness; venous thromboembolism

Indexed keywords

APIXABAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; RIVAROXABAN;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

COST-EFFECTIVENESS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COST-BENEFIT ANALYSIS; DECISION TREES; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MEDICARE; MODELS, THEORETICAL; POSTOPERATIVE COMPLICATIONS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84891814768     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1269     Document Type: Article

References (39)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 381S-453S.
2. American Academy of Orthopaedic Surgeons. Clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. Available from http://www.aaos.org/research/guidelines/Peguide. asp. Accessed June 1, 2012.
3. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
4. Lassen MR, Ageno W, Borris LC, et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358 (26): 2776-86.
5. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676): 1673-80.
6. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010; 375: 807-15.
7. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
8. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. American College of Chest Physicians. Chest 2012; 141 (2 Suppl): e278S-325S.
9. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829-46.
10. Oster G, Tuden R, Colditz GA,. A cost-effectiveness analysis of prophylaxis against deep vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203-8.
11. Menzin J, Colditz G, Regan M, et al. Cost-effectiveness of enoxaparin versus low dose warfarin in the prevention of deep vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-64.
12. Nerurkar J, Wade W, Martin C,. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Pharmacotherapy 2002; 22: 990-1000.
13. Rubinstein J, Murray D, Hoffstein V,. Fatal pulmonary emboli in hospitalized patients: an autopsy study. Ann Intern Med 1988; 148: 1425-6.
14. Douketis J, Kearon C, Bates C,. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-81.
15. Stein P, Andjerald W, Henry M,. Prevalence of acute pulmonary embolism amongst patients in general hospital and at autopsy. Chest 1995; 108: 978-81.
16. Lagerstedt C, Olsson C, Fagher BO,. Need for long term anticoagulant therapy in symptomatic calf vein thrombosis. Lancet 1985; 2: 515-8.
17. Moser KM, LeMoine JR,. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94: 439-44.
18. White R, Romano P, Zhou H,. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-31.
19. Muntz J, Scott DA, Lloyd A, Egger M,. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int J Technol Assess Health Care 2004; 20: 405-14.
20. Neumann I, Rada G, Claro JC, et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012; 156: 710-9.
21. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org. Accessed June 1, 2012.
22. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3 (11): 2479-86.
23. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114 (22): 2374-81.
24. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4 (1): 121-8.
25. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120 (5): 685-93.
26. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5 (12): 2368-75.
27. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632): 31-9.
28. Kanan PS, Schwartsmann CR, Boschin LC, et al. Estudo comparativo entre rivaroxaban e enoxaparina na profilaxia de tromboembolismo venoso profundo em pacientes submetidos à artroplastia total do quadril. Rev Bras Ortop 2008; 43 (8): 319-28.
29. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
30. Fuji T, Wang CJ, Fujita S, et al. Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose-finding study [Abstract 2009]. Available from https://ash.confex.com/ash/2009/webprogram/Paper23718.html. Accessed June 1, 2012.
31. Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial (Abstract 2010). Available from https://ash.confex.com/ash/2010/webprogram/Paper29404.html. Accessed June 1, 2012.
32. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010; 104 (3): 642-9.
33. Cykert S, Phifer N, Hansen C,. Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 2004; 104: 433-42.
34. Aujesky D, Smith KJ, Roberts MS,. Oral anticoagulation strategies after first idiopathic venous thromboembolic event. American J Med 2005; 118: 625-35.
35. Lenert L, Soetikno R,. Automated computer interviews to elicit utilities: potential application in the treatment of deep vein thrombosis. JAMA 1997; 4: 49-56.
36. Fryback D, Lawrence W,. Dollars may not buy as many QALYs as we think: a problem with defining quality of life adjustments. Med Decis Making 1997; 17: 276-84.
37. MacKinnon GE,. Understanding health outcomes and pharmacoeconomincs. Burlington, MA: Jones and Bartlett Learning, 2013: 13.
38. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M,. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. J Med Econ 2011; 14: 824-34.
39. Sobieraj DM, Coleman CI, Tongbram V, et al. Venous thromboembolism in orthopedic surgery. Comparative effectiveness review No. 49. (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I.) AHRQ Publication No. 12-EHC020-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.